Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.30 |
| ▸ | F13A1 | P00488 | 1/20 | 0.30 |
| ▸ | TGM1 | P22735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545174 | 0.87 | THRB (0.32) | APPTHRB | |
| SCHEMBL12427938 | 0.85 | APP (0.39) | CYP3A4CYP2D6OPRK1CA12CA2 | |
| SCHEMBL15544095 | 0.84 | THRB (0.31) | APPTHRB | |
| SCHEMBL15544684 | 0.84 | PKM (0.37) | CA1CA2CYP19A1KMT2ATHRB | |
| SCHEMBL15544218 | 0.84 | GUSB (0.42) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL942630 | 0.82 | LMNA (0.38) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL14042971 | 0.82 | TYMP (0.38) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL12427955 | 0.81 | TYMP (0.37) | CYP3A4CYP2D6OPRK1CA12CA1 | |
| SCHEMBL15544186 | 0.81 | CYP19A1 (0.37) | CYP19A1THRB | |
| SCHEMBL12279600 | 0.81 | KCNH2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9023316-B2 | Synthesis of 18F-labeled tracers in hydrous organic solvents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20130005956-A1 | Synthesis of 18F-labeled Tracers in Hydrous Organic Solvents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2132200-A2 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | Siemens Medical Solutions USA, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008124651-A2 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | HIF1AN, HIF1A, HYOU1 | CYP3A4 581/4885CYP2D6 449/4885OPRK1 1267/4885 |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | CYP3A4 180/4885CYP2D6 110/4885OPRK1 973/4885 |
| US-20130005956-A1 | Synthesis of 18F-labeled Tracers in Hydrous Organic Solvents | SLCO1B1, SLCO4C1, SLCO2B1 | CYP3A4 738/4885CYP2D6 1097/4885OPRK1 349/4885 |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | HIF1AN, HIF1A, HYOU1 | CYP3A4 609/4885CYP2D6 477/4885OPRK1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.